厄洛替尼对比吉西他滨联合顺铂作为IIIA-N2期EGFR突变非小细胞肺癌新辅助治疗(EMERGING-CTONG 1103):一项随机II期研究
本多中心开放标签II期随机对照试验比较厄洛替尼与吉西他滨联合顺铂(GC化疗)用于IIIA-N2期EGFR突变(外显子19或21)非小细胞肺癌的新辅助/辅助治疗。厄洛替尼组新辅助主要终点客观缓解率未达统计学显著(54.1% vs 34.3%,OR 2.26,95%CI 0.87-5.84,P=0.092),但中位无进展生存期显著延长(21.5个月 vs 11.4个月,HR 0.39,95%CI 0.23-0.67,P<0.001)。
要点
- 新辅助厄洛替尼42天对比GC化疗,客观缓解率54.1% vs 34.3%,差异未达统计学显著(P=0.092)。
- 厄洛替尼组中位无进展生存期21.5个月,GC化疗组11.4个月,风险比0.39(95%CI 0.23-0.67,P<0.001)。
- 两组均未发现病理完全缓解;厄洛替尼组主要病理缓解3/31例(9.7%),GC化疗组0/23例。
核心结论
- 42天新辅助厄洛替尼的主要终点客观缓解率未达到,但次要终点无进展生存期显著改善。
研究设计与样本
- 多中心(中国17个中心)、开放标签、II期随机对照试验(EMERGING)。
- 筛查386例,随机分配72例进入意向治疗人群,71例纳入安全性分析(1例治疗前退出)。
- 患者为IIIA-N2期EGFR外显子19或21突变非小细胞肺癌,随机接受厄洛替尼或吉西他滨联合顺铂新辅助/辅助治疗。
主要发现
- 新辅助客观缓解率:厄洛替尼组54.1% vs GC化疗组34.3%(比值比2.26,95%CI 0.87-5.84,P=0.092)。
- 两组均未发现病理完全缓解;主要病理缓解:厄洛替尼组3/31例(9.7%)vs GC化疗组0/23例。
- 中位无进展生存期:厄洛替尼组21.5个月 vs GC化疗组11.4个月(风险比0.39,95%CI 0.23-0.67,P<0.001)。
- 观察到的不良事件反映两种治疗最常见的不良反应。
关键数值与推荐
- 厄洛替尼150 mg/d(新辅助42天;辅助治疗最长12个月)。
- 吉西他滨1,250 mg/m2联合顺铂75 mg/m2(新辅助2周期;辅助治疗最长2周期)。
- 术后6周及之后每3个月评估一次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the benefits of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as neoadjuvant/adjuvant therapies in locally advanced EGFR mutation-positive non-small-cell lung cancer. PATIENTS AND METHODS: This was a multicenter (17 centers in China), open-label, phase II, randomized controlled trial of erlotinib versus gemcitabine plus cisplatin (GC chemotherapy) as neoadjuvant/adjuvant therapy in patients with stage IIIA-N2 non-small-cell lung cancer with EGFR mutations in exon 19 or 21 (EMERGING). Patients received erlotinib 150 mg/d (neoadjuvant therapy, 42 days; adjuvant therapy, up to 12 months) or gemcitabine 1,250 mg/m2 plus cisplatin 75 mg/m2 (neoadjuvant therapy, two cycles; adjuvant therapy, up to two cycles). Assessments were performed at 6 weeks and every 3 months postsurgery. The primary end point was objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; secondary end points were pathologic complete response, progression-free survival (PFS), overall survival, safety, and tolerability. RESULTS: Of 386 patients screened, 72 were randomly assigned to treatment (intention-to-treat population), and 71 were included in the safety analysis (one patient withdrew before treatment). The ORR for neoadjuvant erlotinib versus GC chemotherapy was 54.1% versus 34.3% (odds ratio, 2.26; 95% CI, 0.87 to 5.84; P = .092). No pathologic complete response was identified in either arm. Three (9.7%) of 31 patients and zero of 23 patients in the erlotinib and GC chemotherapy arms, respectively, had a major pathologic response. Median PFS was significantly longer with erlotinib (21.5 months) versus GC chemotherapy (11.4 months; hazard ratio, 0.39; 95% CI, 0.23 to 0.67; P < .001). Observed adverse events reflected those most commonly seen with the two treatments. CONCLUSION: The primary end point of ORR with 42 days of neoadjuvant erlotinib was not met, but the secondary end point PFS was significantly improved.
引用
- Zhong WZ, Chen KN, Chen C, et al. Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. J Clin Oncol. 2019. PMID: 31194613. doi:10.1200/JCO.19.00075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。